SCHEMBL4774988

SCHEMBL4774988

COc1ccc(OC)c(-c2cc3ccccc3c(Cl)n2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.48
MAPK1 P28482 1/20 0.48
RECQL P46063 1/20 0.48
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ADORA3 P0DMS8 2/20 0.44
NPC1 O15118 1/20 0.44
ENPP3 O14638 1/20 0.44
ENPP1 P22413 1/20 0.44
PIM1 P11309 1/20 0.44
NQO1 P15559 1/20 0.44
APAF1 O14727 1/20 0.43
TDP2 O95551 1/20 0.43
CDC25B P30305 1/20 0.43
CASP3 P42574 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765203 0.89 MEN1 (0.55) CYP2D6CYP2C9L3MBTL1KDM4EALDH1A1
SCHEMBL4773825 0.85 HSP90AA1 (0.56) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL4769077 0.84 MEN1 (0.44) CYP2D6CYP2C9L3MBTL1KDM4EALDH1A1
SCHEMBL4773101 0.83 HSP90AA1 (0.51) CYP2D6CYP2C9MAPK1KDM4EALDH1A1
SCHEMBL4763954 0.80 NPC1 (0.58) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL4766383 0.78 ADORA2A (0.46) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL4771340 0.77 KMT2A (0.61) L3MBTL1MAPK1KDM4EALDH1A1HPGD
SCHEMBL4769223 0.77 CYP1A2 (0.48) CYP2D6CYP2C9MAPK1ALDH1A1HPGD
SCHEMBL4772286 0.77 CASP3 (0.48) CYP2D6CYP2C9L3MBTL1KDM4EALDH1A1
SCHEMBL4771500 0.76 CCR1 (0.57) MAPK1ADORA3NPC1CYP17A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 CYP2D6 3573/4885CYP2C9 2491/4885L3MBTL1 4124/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 CYP2D6 2558/4885CYP2C9 2660/4885L3MBTL1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.